

Correction: Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

Mayadev J, Zamarin D, Deng W, *et al.* Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. *Int J Gynecol Cancer* 2019. doi: 10.1136/ijgc-2019-001012.

Since the online publication of this article, the authors have noticed that their funding statement incorrectly states 'The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors'. The correct funding statement is 'This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office, NRG Oncology Statistics and Data Management Center (U10 CA180822) and NRG Oncology Operations Center (U10CA180868)'

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Int J Gynecol Cancer 2020;0:1. doi:10.1136/ijgc-2019-001012corr1

